Print

BioSante Pharmaceuticals, Inc. (BPAX) Receives NASDAQ Delisting Determination Letter  
6/21/2013 9:56:03 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BAUDETTE, Minn.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced today that on June 20, 2013, it received a letter from NASDAQ informing BioSante that, since the merger with ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc. (ANI) constituted a business combination resulting in a change of control under Listing Rule 5110(a), BioSante was required to meet the initial listing criteria for the NASDAQ Global Market. The letter continued that, since BioSante did not meet the minimum $4 bid price requirement for initial listings under Listing Rule 5405(a)(1), NASDAQ had determined to delist BioSante’s securities, and that BioSante could appeal this determination.

Help employers find you! Check out all the jobs and post your resume.

//-->